Biocon Q1 Results FY2027: Revenue Rises 10% YoY, PAT Jumps 53% to ₹137 Cr
Biocon reports steady Q1 FY27 performance with revenue up 10% YoY, PAT rising 53%, led by strong Biosimilars and Generics growth.
Biocon Q1 Results FY2027: Biocon reported a healthy performance in Q1 FY27, supported by steady growth in its Biosimilars and Generics businesses. Despite a sequential decline in revenue and operating margin, improved profitability led to a strong year-on-year increase in net profit during the quarter.
Biocon Q1 Results FY2027: On 5 August 2026, Biocon announced its financial results for the first quarter ended 30 June 2026. Revenue from Operations increased 10.00% YoY to ₹4,336 crore compared with ₹3,942 crore in Q1 FY26.
While Profit After Tax (PAT) increased 53.36% YoY to ₹137 crore compared with ₹89 crore in Q1 FY26. EBITDA Margin stood at 19.54% during the quarter.
Biocon share price closed 0.76% higher on 5 August 2026. The stock has delivered 10% returns year-to-date and 14% returns over the one year from 5 August 2025 to 5 August 2026.
As of 5 Aug, 3:30 PM
READ THIS ALSO: Navin Fluorine Q1 Results FY2027
Biocon Q1 FY27 Results Highlights
-
Revenue from Operations stood at ₹4,336 crore, registering a 10.00% YoY increase from ₹3,942 crore in Q1 FY26. Compared with ₹4,517 crore in Q4 FY26, revenue declined 4.00% QoQ.
-
Total Revenue stood at ₹4,391 crore, registering a 9.17% YoY increase from ₹4,022 crore in Q1 FY26. Compared with ₹4,569 crore in Q4 FY26, total revenue declined 3.91% QoQ.
-
EBITDA (Excluding Other Income) stood at ₹847 crore, compared with ₹766 crore in Q1 FY26, registering a 10.59% YoY increase. Compared with ₹1,020 crore in Q4 FY26, EBITDA declined 16.97% QoQ.
-
EBITDA Margin stood at 19.54%, compared with 19.43% in Q1 FY26 and 22.59% in Q4 FY26, improving by 0.10 percentage points YoY and declining by 3.05 percentage points QoQ.
-
Profit After Tax (PAT) stood at ₹137 crore, compared with ₹89 crore in Q1 FY26, registering a 53.36% YoY increase. Compared with ₹199 crore in Q4 FY26, PAT declined 31.12% QoQ.
-
PAT Margin stood at 3.15%, compared with 2.26% in Q1 FY26 and 4.40% in Q4 FY26, improving by 0.89 percentage points YoY and declining by 1.24 percentage points QoQ.
-
Profit After Tax attributable to owners of the company stood at ₹141 crore, compared with ₹31 crore in Q1 FY26, registering a 349.36% YoY increase. Compared with ₹126 crore in Q4 FY26, PAT attributable to owners increased 12.07% QoQ.
-
EPS stood at ₹0.87, compared with ₹0.26 in Q1 FY26 and ₹0.79 in Q4 FY26, increasing 234.62% YoY and 10.13% QoQ.
|
Metric |
Q1 FY27 |
Q4 FY26 |
QoQ % |
Q1 FY26 |
YoY % |
|---|---|---|---|---|---|
|
Revenue from Operations (₹ Cr) |
4,336 |
4,517 |
-4.00% |
3,942 |
10.00% |
|
Total Revenue (₹ Cr) |
4,391 |
4,569 |
-3.91% |
4,022 |
9.17% |
|
EBITDA (Excl. Other Income) (₹ Cr) |
847 |
1,020 |
-16.97% |
766 |
10.59% |
|
EBITDA Margin |
19.54% |
22.59% |
-3.05 pp |
19.43% |
+0.10 pp |
|
PAT (₹ Cr) |
137 |
199 |
-31.12% |
89 |
53.36% |
|
PAT Margin |
3.15% |
4.40% |
-1.24 pp |
2.26% |
+0.89 pp |
|
PAT (Owners) (₹ Cr) |
141 |
126 |
12.07% |
31 |
349.36% |
|
EPS (₹) |
0.87 |
0.79 |
10.13% |
0.26 |
234.62% |
Biocon Q1 Segment-wise Performance
Biocon reported mixed performance across its business segments during Q1 FY27. The Biosimilars and Generics businesses recorded healthy year-on-year growth, while the Services segment witnessed a decline in revenue. Biosimilars continued to remain the largest contributor to the company's overall revenue during the quarter.
|
Segment (₹ Cr) |
Q1 FY27 |
Q4 FY26 |
QoQ % |
Q1 FY26 |
YoY % |
|---|---|---|---|---|---|
|
Biosimilars |
2,855.60 |
2,756.00 |
3.63% |
2,457.80 |
16.19% |
|
Generics |
759.70 |
776.00 |
-2.10% |
630.30 |
20.53% |
|
Services |
736.00 |
1,037.00 |
-28.99% |
874.50 |
-15.84% |
|
Less: Inter Segment Revenue |
15.30 |
52.00 |
-70.29% |
20.70 |
-26.09% |
|
Total Revenue from Operations |
4,336.00 |
4,517.00 |
-4.00% |
3,941.90 |
10.00% |
Source: Company Filing
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.